TrialLipids in health and disease2017

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.

Joshua Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.